neDNA™ is designed to transform and accelerate the traditional gene therapy development timelines. At TAAV we produce enzymatic DNA as an alternative to plasmids DNA for the manufacture of adeno-associated virus (AAV). Our disruptive technology is creating a new industry standard for transfection-based rAAV production. The synthetic process we use leads to high yields shortening manufacturing timelines, facilitating quicker production of rAAV and potentially increasing safety by virtually eliminating bacterial sequences that are present when using plasmid DNA.
Plasmids have several major bottlenecks in gene therapy manufacturing, and one specifically that we solve with neDNA™: Production of plasmids may result in their genetic instability, which makes them susceptible to changes in sequence, particularly when encoding complex viral vectors. Our neDNA™ approach intends to be safer producing higher and faster yields at lower costs than plasmid.
- Likely Safer
- Higher Yield
- Scalable
- Faster to Manufacture
- Robust